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PODIUM SESSION I: ECONOMIC EVALUATIONS I
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DISCRETE CHOICE EXPERIMENTS OF COMPLEX HEALTH
CARE DECISIONS: DOES HIERARCHICAL INFORMATION
INTEGRATION OFFER A SOLUTION?
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Von Meyenfeldt M1, Dirksen CD1
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OBJECTIVES: Discrete choice experiments (DCE) are increas-
ingly used to investigate preferences for health care products and
programs. A limitation of DCE is the inability to handle large
numbers of attributes. In hierarchical information integration
(HII) attributes are categorized into meaningful subsets, and
separate experiments are designed for each of the subsets. A
HII-DCE was applied regarding potential barriers and facilita-
tors to implementation of the guideline for breast cancer surgery
in day-care. METHODS: A total of 1713 questionnaires were
sent to three groups of health care professionals (anesthesiolo-
gists, surgical oncologists, breast care nurses). Random param-
eters logit modelling was used to estimate a choice model.
Theoretical validity, construct validity, and internal consistency
were assessed to investigate whether HII can be used to deal with
the typical complexity of multi-faceted health care management
decisions. Also, response rate and predictive ability of the model
were assessed to study the feasibility of HII. RESULTS: Sixteen
out of 17 attributes were signiﬁcant at the 1% level and had the
expected sign. Also all three decision constructs were signiﬁcant
at the 1% level, and were well deﬁned by their attributes. The
test-retest resulted in a Kappa statistic of 0.58 (p < 0.001). The
overall response rate was 10%. The predicted frequency distri-
bution and observed frequency distribution based on the full
proﬁle hold-out task did not differ signiﬁcantly (Chi-square test;
p = 0.088). CONCLUSIONS: Our study showed good theoreti-
cal validity, good construct validity and satisfactory internal con-
sistency. Response rate was poor and predictive ability of the
model was satisfactory. In conclusion, HII can be successfully
used to study complex health care decisions. The feasibility of
HII in this particular context of an implementation decision
seemed less favourable.
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OBJECTIVES: The American Diabetes Association (ADA) has
estimated the annual cost of diabetes in the USA at $174 billion
(ADA, Diabetes Care, 2008), using multiple and varied sources
to derive cost estimates. This study used a single, multi-payer US
database to derive private payer-speciﬁc estimates of average type
2 diabetes mellitus (T2DM) complication costs, which may be
suitable for long-term economic modeling. METHODS: Private
health insurance claims were taken from the PharMetrics Patient-
Centric Database, which is comprised of adjudicated medical and
pharmaceutical claims covering 55 million unique patients from
over 90 health plans from across the USA. T2DM patients expe-
riencing at least 1 of 24 major complications from July 1, 2003
through June 30, 2005, along with a T2DM diagnosis prior to or
on the date of the index complication, were identiﬁed. T2DM
complication costs were extracted from 64,556 patients who had
a minimum of 12 months follow-up. Cost data for months 13–24
following the complication were taken from a subset of the full
patient population who were continuously eligible for at least 24
months (n = 47,541). Direct medical costs were subdivided into
charges and allowed amounts expressed in $US 2007. RESULTS:
The average age of the population was 57 years and 51.8% were
male. The most frequently reported complication was peripheral
neuropathy (26.3%). First year charges for complications ranged
between $272 for ketoacidosis to $38,588 for myocardial infarc-
tion, with corresponding allowed amounts of $174 and $14,394,
respectively. Second year charges for complications ranged
between $0 for ketoacidosis to $21,965 for peritoneal dialysis,
with corresponding allowed amounts of $0 and $10,133, respec-
tively. Among all complications, allowed amounts were sig-
niﬁcantly lower than charged amounts. CONCLUSIONS: Our
study provides an important and representative source of T2DM
complication costs for estimating the long-term economic impact
of this prevalent and costly disease.
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VARIATION IN DIRECT MEDICAL COSTS BY DISEASE
SEVERITY AMONG PERSONS WITH CHRONIC HEPATITIS
CVIRUS
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OBJECTIVES: To document disease-related resource utilization
and costs by disease severity among persons with chronic hepatitis
C virus (HCV) in a United States (US) managed care population.
METHODS:AUS insurance claims database spanning January 1,
2002 toDecember 31, 2006was retrospectively analyzed. Patients
with1 diagnosis of chronic HCV and no evidence of hepatitis B
were selected. Patients had continuous plan enrollment for 6
months before and 12 months following ﬁrst observed HCV
diagnosis. Disease severity, measured using the aspartate ami-
notransferase to platelet ratio index (APRI), was assessed for
patients with valid lab results (N = 2877). Patients were classiﬁed
into three mutually exclusive severity categories: mild (APRI 
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